Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

tetra logo

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Guy Chamberland

 

 

 

 

 

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.

Investor Presentation Deck
Tetra Investor Presentation




Related Articles

Newsmakers

Medicine Man Technologies (OTC: MDCL) Highlights Landmark Consolidation Strategy To Create One Of North America’s Largest Vertically Integrated Cannabis Operators. Projected Annual Revenues From The Previously Disclosed Proposed Acquisitions Total Approximately $170 Million In 2019

September 16, 2019 admin Newsmakers Comments Off on Medicine Man Technologies (OTC: MDCL) Highlights Landmark Consolidation Strategy To Create One Of North America’s Largest Vertically Integrated Cannabis Operators. Projected Annual Revenues From The Previously Disclosed Proposed Acquisitions Total Approximately $170 Million In 2019

DENVER, Sept. 16, 2019 — Medicine Man Technologies, Inc. (OTC: MDCL) (“Medicine Man Technologies” or the “Company”) announced a culmination of its roll-up strategy today that would solidify the Company as one of the largest vertically integrated cannabis […]

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH

October 3, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH

VANCOUVER, Washington, Oct. 01, 2019– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today FDA clearance […]